HUE064694T2 - Továbbítószert tartalmazó készítmények és elõállításuk - Google Patents

Továbbítószert tartalmazó készítmények és elõállításuk

Info

Publication number
HUE064694T2
HUE064694T2 HUE18212576A HUE18212576A HUE064694T2 HU E064694 T2 HUE064694 T2 HU E064694T2 HU E18212576 A HUE18212576 A HU E18212576A HU E18212576 A HUE18212576 A HU E18212576A HU E064694 T2 HUE064694 T2 HU E064694T2
Authority
HU
Hungary
Prior art keywords
compositions
preparation
delivery agent
delivery
agent
Prior art date
Application number
HUE18212576A
Other languages
English (en)
Inventor
Thomas Vilhelmsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49221869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE064694(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of HUE064694T2 publication Critical patent/HUE064694T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE18212576A 2012-03-22 2013-03-15 Továbbítószert tartalmazó készítmények és elõállításuk HUE064694T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12160742 2012-03-22
US201361748844P 2013-01-04 2013-01-04
EP13153422 2013-01-31

Publications (1)

Publication Number Publication Date
HUE064694T2 true HUE064694T2 (hu) 2024-04-28

Family

ID=49221869

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18212576A HUE064694T2 (hu) 2012-03-22 2013-03-15 Továbbítószert tartalmazó készítmények és elõállításuk

Country Status (11)

Country Link
US (1) US10335369B2 (hu)
EP (3) EP4331667A3 (hu)
JP (1) JP6356660B2 (hu)
CN (3) CN104203221A (hu)
ES (1) ES2965469T3 (hu)
HR (1) HRP20231613T1 (hu)
HU (1) HUE064694T2 (hu)
PL (2) PL3542790T3 (hu)
RS (2) RS58636B1 (hu)
SI (1) SI2827845T1 (hu)
WO (1) WO2013139695A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
EP3225631B1 (en) 2011-04-12 2019-01-09 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104203221A (zh) 2012-03-22 2014-12-10 诺和诺德A/S（股份有限公司） 包含递送剂的组合物及其制备
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
PT2827845T (pt) * 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
CN104173313B (zh) * 2014-08-25 2017-05-17 杭州朱养心药业有限公司 利伐沙班片剂药物组合物
WO2016115082A1 (en) 2015-01-12 2016-07-21 Enteris Biopharma, Inc. Solid oral dosage forms
CN108883073B (zh) * 2016-12-30 2021-10-08 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
SG11202006595RA (en) 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020152304A1 (en) * 2019-01-24 2020-07-30 Novo Nordisk A/S Roller compactor and method of dry granulation using a roller compactor
CA3144618A1 (en) * 2019-08-07 2021-02-11 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114340655A (zh) 2019-09-02 2022-04-12 诺和诺德股份有限公司 生产包含glp-1肽的片剂的方法
JP2022547094A (ja) 2019-09-06 2022-11-10 ノヴォ ノルディスク アー／エス 医薬組成物における使用のための顆粒の分別のための方法および機器
JP2023502004A (ja) 2019-11-07 2023-01-20 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬、ｓｇｌｔ２阻害剤、およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
JP2023524695A (ja) 2020-04-29 2023-06-13 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
JP2023534131A (ja) 2020-07-22 2023-08-08 ノヴォ ノルディスク アー／エス 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬
IL299707A (en) * 2020-07-22 2023-03-01 Novo Nordisk As Co-agonists for GLP-1 and GIP receptors
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
BR112023022400A2 (pt) 2021-05-07 2024-01-16 Lilly Co Eli Comprimido erodível, método de fabricação e usos do mesmo
JP2024525377A (ja) * 2021-07-15 2024-07-12 ノヴォ ノルディスク アー／エス Ｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む錠剤
AU2022401780A1 (en) * 2021-12-01 2024-07-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
IE62126B1 (en) 1986-03-12 1994-12-14 American Cyanamid Co Macrolide compounds
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
DE60038097T2 (de) 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CA2442280A1 (en) 2001-03-27 2002-10-03 Ranbaxy Laboratories Limited A stable pharmaceutical composition of pravastatin
CN1527700A (zh) 2001-05-15 2004-09-08 ��������ʲ��������ι�˾ 制备苯妥英钠剂型的压缩方法
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
EP1461031B1 (en) 2001-11-29 2016-06-29 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
BR0307331A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina
WO2003072195A2 (en) 2002-02-20 2003-09-04 Eli Lilly And Company Method for administering glp-1 molecules
JP2004131398A (ja) * 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
BRPI0411165A (pt) 2003-05-14 2006-07-11 Emisphere Tech Inc composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
JP5032844B2 (ja) 2003-07-11 2012-09-26 ノバルティス アーゲー 微粉末形態の送達物質を含む経口投与用医薬組成物
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ 新規なｇｌｐ−１化合物
KR20060109940A (ko) 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
RU2006138703A (ru) * 2004-05-06 2008-06-20 Эмисфире Текнолоджис Твердая лекарственная форма увлажненного гепарина
WO2005107462A2 (en) 2004-05-06 2005-11-17 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
US8273794B2 (en) 2004-05-14 2012-09-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2005115347A1 (en) 2004-05-31 2005-12-08 Sam-A Pharmaceuticals Co., Ltd. Dispersible tablet comprising beta lactam antibiotics and process for preparing the same
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
AU2005261740A1 (en) 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US20060078622A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
EP1799710A2 (en) 2004-10-07 2007-06-27 Novo Nordisk A/S Protracted glp-1 compounds
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
ES2755273T3 (es) 2004-12-03 2020-04-22 Merck Sharp & Dohme Formulación farmacéutica de inhibidores de la carboxamida VIH integrasa que contienen una composición de control de la velocidad de liberación
ES2540929T3 (es) 2005-02-01 2015-07-14 Emisphere Technologies, Inc. Sistema de administración de retención gástrica y liberación controlada
MX2007011307A (es) 2005-03-18 2007-10-08 Novo Nordisk As Compuestos de glp-1 extendidos.
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1863449A2 (en) 2005-03-28 2007-12-12 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
JP2009515993A (ja) 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
CA2654566A1 (en) 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2008003050A2 (en) * 2006-06-28 2008-01-03 Emisphere Technologies, Inc. Gallium nitrate formulations
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
WO2008023050A1 (en) 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
AU2007293916B2 (en) 2006-09-07 2011-02-03 Emisphere Technologies, Inc. A process for the manufacture of SNAC (salcaprozate sodium)
PE20080845A1 (es) 2006-09-22 2008-08-13 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
US20100069410A1 (en) * 2006-12-01 2010-03-18 Emisphere Technologies Inc. acyclovir formulations
EP2131810B1 (en) 2007-03-02 2011-05-04 Novartis AG Oral administration of a calcitonin
WO2009032749A2 (en) 2007-08-29 2009-03-12 The Regents Of The University Of Californina Salicylanilide modified peptides for use as oral therapeutics
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
JP2010538049A (ja) 2007-09-05 2010-12-09 ノボ・ノルデイスク・エー／エス 切断型ｇｌｐ−１誘導体及びその治療的使用
US8895694B2 (en) 2007-09-05 2014-11-25 Novo Nordisk A/S Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
CN101939023B (zh) 2007-10-16 2016-08-03 百康有限公司 可经口给药的固体药物组合物及其方法
WO2009059188A1 (en) 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
US20090124639A1 (en) 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
EP3741359A1 (en) * 2008-08-18 2020-11-25 Entera Bio Ltd. Methods and compositions for oral administration of proteins
CA2752437C (en) 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2011116139A2 (en) 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
EP3150198B1 (en) 2010-04-07 2021-09-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
CN104203221A (zh) 2012-03-22 2014-12-10 诺和诺德A/S（股份有限公司） 包含递送剂的组合物及其制备
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds

Also Published As

Publication number Publication date
EP3542790B1 (en) 2023-09-13
RS58636B1 (sr) 2019-05-31
RS64942B1 (sr) 2024-01-31
JP6356660B2 (ja) 2018-07-11
EP2827845A1 (en) 2015-01-28
PL3542790T3 (pl) 2024-02-26
HRP20231613T1 (hr) 2024-03-15
CN104203221A (zh) 2014-12-10
CN111494324B (zh) 2023-05-16
US10335369B2 (en) 2019-07-02
EP4331667A2 (en) 2024-03-06
ES2965469T3 (es) 2024-04-15
WO2013139695A1 (en) 2013-09-26
SI2827845T1 (sl) 2019-04-30
EP3542790C0 (en) 2023-09-13
EP3542790A1 (en) 2019-09-25
JP2015515459A (ja) 2015-05-28
CN111494323B (zh) 2023-03-28
CN111494323A (zh) 2020-08-07
CN111494324A (zh) 2020-08-07
US20150031606A1 (en) 2015-01-29
EP4331667A3 (en) 2024-05-08
EP2827845B1 (en) 2018-12-26
PL2827845T3 (pl) 2019-06-28

Similar Documents

Publication Publication Date Title
EP3542790C0 (en) COMPOSITIONS COMPRISING AN ADMINISTRATIVE AGENT AND THEIR PREPARATION
IL286348A (en) Pharmaceutical preparations that include allopregnanolone
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
ZA201703992B (en) Inhalable pharmaceutical compositions
HRP20190489T1 (hr) Pripravci koji sadrže sredstvo za unošenje i njihova priprava
IL252566A0 (en) Pharmacy preparations and methods
HK1195793A1 (zh) 結合藥物組合物及其用途
HK1201152A1 (en) Dermal delivery compositions and methods
IL236268A0 (en) Preparations for mucosal administration and their uses
IL236358B (en) Medicinal preparations containing hormone replacements and their use
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
EP2775831A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP2753341A4 (en) ANTIMICROBIAL COMPOSITIONS AND USES THEREOF
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
PL2908837T3 (pl) Kompozycje do dostarczania leku
ZA201307837B (en) Compositions comprising antibacterial agent and tazobactam
ZA201504512B (en) Pharmaceutical composition comprising desloratadine and prednisolone and use thereof
GB201208315D0 (en) Pharmaceutical methods and compositions
EP2926811A4 (en) ARTEMISCULAR PHARMACEUTICAL COMPOSITION, MANUFACTURE AND USE
EP2834635A4 (en) COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR
EP2838365A4 (en) ANTIMICROBIAL COMPOSITIONS AND USES THEREOF
GB201219884D0 (en) New composition and preparation thereof
GB201110598D0 (en) Pharmaceutical compositions and devices